Literature DB >> 23010650

Contribution of the OATP1B subfamily to cancer biology and treatment.

T M Sissung1, K M Reece, S Spencer, W D Figg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23010650      PMCID： PMC6691887          DOI： 10.1038/clpt.2012.127

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

1.  Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Authors:  Tristan M Sissung; Ariel M Ley; Jonathan D Strope; Edel M McCrea; Shaunna Beedie; Cody J Peer; Suneet Shukla; Jennifer van Velkinburgh; Kelie Reece; Sarah Troutman; Tessa Campbell; Elena Fernandez; Phoebe Huang; Jordan Smith; Nilay Thakkar; David J Venzon; Stefan Brenner; Wooin Lee; Maria Merino; Ji Luo; Walter Jager; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Mol Cancer Res       Date:  2017-04-07       Impact factor: 5.852

Review 2.  Androgen receptor variation affects prostate cancer progression and drug resistance.

Authors:  Edel McCrea; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Pharmacol Res       Date:  2016-10-07       Impact factor: 7.658

3.  Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Authors:  Krystyna M Wozniak; James J Vornov; Ying Wu; Kenichi Nomoto; Bruce A Littlefield; Christopher DesJardins; Yanke Yu; George Lai; Larisa Reyderman; Nancy Wong; Barbara S Slusher
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

Review 4.  Organic anion-transporting polypeptides.

Authors:  Bruno Stieger; Bruno Hagenbuch
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

5.  Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.

Authors:  Xinrun Ma; Xuyang Shang; Xuan Qin; Jian Lu; Mingyao Liu; Xin Wang
Journal:  Acta Pharm Sin B       Date:  2019-11-14       Impact factor: 11.413

6.  Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis.

Authors:  Tiantian Tang; Guiying Wang; Sihua Liu; Zhaoxue Zhang; Chen Liu; Fang Li; Xudi Liu; Lingjiao Meng; Huichai Yang; Chunxiao Li; Meixiang Sang; Lianmei Zhao
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.